Professor Mallika Imwong
Malariologist at Mahidol Department of Molecular Tropical Medicine and Genetics
- Honorary Visiting Research Fellow in Tropical Medicine
My research works have focused on three aspects:
- to understand how drug resistance emerges and spreads in malaria parasites in Asia and Africa
- to detect and characterise the true epidemiology of malaria in low transmissions setting
- to investigate the biology of relapse of benign malaria.
I am currently involved in surveillance studies describing the molecular epidemiology of drug resistance in different parts of the region including Thai-Burmese border, Eastern Thailand, Cambodia, Vietnam, Laos PDA, and Afghanistan. A key objective is to determine the genetic and mechanistic basis for increased resistance of P. falciparum to artemisinin. The development of an inexpensive and effective genetic tool is essential for public health monitoring for artemisinin resistance. My ongoing projects will use genotyping markers or phenotypic properties for the fitness cost alleviating genetic variants validated loci and conduct follow-up molecular epidemiological surveys to assess their prevalence throughout the GMS in the current state of transmission. Therefore, this will also allow us to assess the potential of the GMS to develop drug resistance phenotypes and to evaluate the potential that such phenotypes emerge in other parts of the malaria world (such as Africa), as control programs progress towards elimination.
Transnational spread of multidrug resistant PfPailin
Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial
Tripura R. et al, (2023), The Lancet Infectious Diseases, 23, 81 - 90
Drug resistance of Plasmodium falciparum and Plasmodium vivax isolates in Indonesia.
Rahmasari FV. et al, (2022), Malaria journal, 21
Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia.
Cutts JC. et al, (2022), The Journal of infectious diseases, 226, 324 - 331
Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
Peto TJ. et al, (2022), The Lancet Infectious Diseases, 22, 867 - 878
Comparative analysis of targeted next-generation sequencing for Plasmodium falciparum drug resistance markers.
Kunasol C. et al, (2022), Scientific reports, 12